Invest Securities announced this morning that it is maintaining its 'neutral' recommendation on Medesis shares, with an unchanged target price of 3.3 euros.

While the Montpellier Commercial Court has ordered Medesis to pay 1.4 ME to Bpifrance, 'Medesis has decided to appeal this judgment after announcing its first intention to discuss with Bpifrance management to identify a suitable repayment plan', reports

' At this stage, we have identified 3 possible scenarios, the central scenario being the most likely if Medesis manages to demonstrate that the subsidies received (representing almost half of the sum demanded by Bpifrance) and theoretically non-refundable, do not have to be repaid as part of this litigation', the broker says.

For its part, Medesis continues to make progress on its R&D programs, for which some delays are to be expected in the short term, adds Invest.


Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.